Clinical trial • Phase I • Gastroenterology

LIV001 for Ulcerative colitis

Phase I trial of LIV001 for Ulcerative colitis. Randomised, placebo (dose and schedule not specified)-controlled. 8 participants.

Overview

Trial Therapeutic Area
Gastroenterology
Trial Disease
Ulcerative colitis
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
23-07-2024
First CTIS Authorization Date
18-11-2024

Trial design

Randomised, placebo (dose and schedule not specified)-controlled Phase I trial across 3 sites in Poland.

Randomised
Yes
Comparator
Placebo (dose and schedule not specified)
Target Sample Size
8
Trial Duration For Participant
336

Recruitment

Planned Sample Size
8
Recruitment Window Months
11

Geography

Total Number Of Sites
3
Total Number Of Participants
8

Poland

Earliest CTIS Part Ii Submission Date
25-10-2024
Latest Decision Or Authorization Date
02-03-2025
Processing Time Days
128
Number Of Sites
3
Number Of Participants
8

Sites

Site Name
Provita Poliklinika Sp. z o.o.
Department Name
Gastroenterology
Principal Investigator Name
Marek Bugajski
Principal Investigator Email
marek.bugajski@gmail.com
Contact Person Name
Marek Bugajski
Contact Person Email
marek.bugajski@gmail.com
Site Name
Centrum Medyczne Medyk Sp. z o.o.
Department Name
Gastroenterology
Principal Investigator Name
Rafał Filip
Principal Investigator Email
r.filip.medyk@gmail.com
Contact Person Name
Rafał Filip
Contact Person Email
r.filip.medyk@gmail.com
Site Name
Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
Department Name
Gastroenterology
Principal Investigator Name
Piotr Napora
Principal Investigator Email
napora.piotr@cbk.wroc.pl
Contact Person Name
Piotr Napora
Contact Person Email
napora.piotr@cbk.wroc.pl

Sponsor

Primary sponsor

Full Name
Liveome Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Korea, Republic of

Investigational products

Investigational Product Name
LIV001

Related trials

Other published trials that may interest you.